Tuesday, March 18, 2025 | 01:11 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Trump's focus on local drugs not immediate concern: Indian pharma industry

US is one of the major export destinations for drugmakers in India, accounting for roughly 33 per cent of the country's drug exports

The government is now trying to understand how long it will take before the drug’s production can start in India
Premium

President Donald Trump's administration awarded a contract worth up to $812 million over ten years to a newly incorporated US company called Phlow Corporation

Sohini Das Mumbai
As the US tries to reduce dependence on drugs from other countries, especially essential generic drugs, demand issues can arise for Indian exporters. The local industry in India, however, feels that creating indigenous capacity to manufacture drugs would take time, and also prove to be expensive for the US.

President Donald Trump's administration awarded a contract worth nearly $812 million over ten years to a newly incorporated US company called Phlow Corporation to manufacture drugs and even active pharmaceutical ingredients (APIs) in the US to fight Covid-19.

US is one of the major export destinations for drugmakers in India, accounting

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in